Latest DORSAVI (ASX:DVL) News

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

dorsaVi has launched a multi-year collaboration with leading Asian research institutes to develop its proprietary RRAM technology at the 22-nanometer node, targeting AI-driven robotics and wearable applications.

DorsaVi reports significant progress in its resistive RAM (RRAM) development, optimizing memory technology for integration with neuromorphic computing at the 22nm technology node. This advancement positions the company to deliver energy-efficient edge-AI solutions for wearables, robotics, and industrial safety.

dorsaVi Limited has acquired a cutting-edge neuromorphic processing-in-memory technology portfolio, positioning itself at the forefront of next-generation wearable and robotics intelligence. This strategic move, coupled with leadership changes, signals a new era for the company’s adaptive biosensor and robotics platforms.

dorsaVi has launched an evaluation program to scale its oxide-based RRAM technology from 40 nm to 22 nm, aiming for significant gains in density, speed, and energy efficiency. This move could enhance its wearable sensor devices and embedded AI applications.

dorsaVi reports breakthrough RRAM sensor performance and secures a major US physical therapy deal, backed by a $5 million capital raise and new leadership appointments.

dorsaVi reports a striking 15-fold increase in US Physical Therapy clinic subscriptions for its ViMove+ product, driven by strong surgeon endorsements and a successful face-to-face training rollout.

dorsaVi has confirmed its RRAM Reflex Platform achieves biological-grade reflexes with sub-microsecond latency and ultra-low energy use, outperforming leading digital edge AI systems by orders of magnitude.

dorsaVi has achieved a major engineering milestone by validating its RRAM-powered Reflex Platform, delivering neural reflex decisions in under one microsecond with ultra-low energy consumption. This breakthrough paves the way for next-generation robotics, prosthetics, and wearable devices that require rapid, energy-efficient reflex actions.

dorsaVi has inked a five-year sales agreement with Select Medical, opening access to over 1,900 US outpatient physical therapy centers for its FDA-approved motion analysis products. This follows a successful 18-month pilot validating clinical benefits in athlete rehabilitation.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.